View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 31, 2018

AstraZeneca reports negative findings from TERRANOVA trial

AstraZeneca and its research and development arm MedImmune have reported negative top-line results from the TERRANOVA trial after it failed to meet its primary objective. 

AstraZeneca and its research and development arm MedImmune have reported negative top-line results from the TERRANOVA trial after it failed to meet its primary objective.

However, the safety and tolerability results were similar to those observed in previous trials of Fasenra.

TERRANOVA is AstraZeneca’s second of the two pivotal Phase III trials designed to evaluate Fasenra (benralizumab) in patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

The randomised, double-blinded, 56-week placebo-controlled, multicentre trial’s primary objective included a statistically significant reduction of exacerbations in COPD patients.

“These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options.”

The trial evaluated the safety and efficacy of Fasenra as an add-on to dual or triple inhaled therapy against placebo in patients with moderate to very severe COPD with a history of exacerbations across a range of baseline blood eosinophils.

Findings of the TERRANOVA trial follow negative results from the company’s first pivotal Phase III trial of Fasenra for COPD, GALATHEA. The results were reported earlier this month.

AstraZeneca Global Medicines Development executive vice-president and chief medical officer Dr Sean Bohen said: “These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options.

“We will now analyse the complete data sets from the GALATHEA and TERRANOVA trials to further understand these results.”

The company currently has no plan to submit a regulatory application for Fasenra, which is a monoclonal antibody that hires natural killer cells to induce rapid and near-complete depletion of eosinophils, a type of white blood cell that is a normal part of the body’s immune system.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU